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Background/aim: Various COVID-19 vaccines are being developed around the world. Important questions to be answered regarding
vaccines are efficacy, safety, and whether antibodies are protective when used in different communities. This study aimed to determine
seroconversion rates of the inactivated SARS-CoV-2 vaccine in healthcare workers in a hospital and short-term adverse events due to
the vaccine.
Materials and methods: The study carried out in Çukurova University, Turkey, comprised of 282 healthcare workers who received two
doses of the inactivated SARS-CoV-2 vaccine administered in two 3 µg doses, 28 days apart. On day 28, after the second dose, antiS-RBD IgG and total anti-spike and anti-nucleocapsid IgM and IgG antibodies against SARS-CoV-2 were detected by using in vitro
chemiluminescence immunoassay method.
Results: The mean age of participants was 39.06±10.65 (min=21, max=65) with 43.6% males and 56.4% females. On day 28, after
the second dose, the seroconversion rates were found to be 92.9% for total anti-spike and anti-nucleocapsid IgG and 15.2% for IgM
and 98.2% for anti-S-RBD IgG antibodies and having natural COVID-19 prior to vaccination, age and comorbidity were found to be
significant factors for immunogenicity. The incidence of at least one adverse event was found as 29.8% after the first dose and 24.1% after
the second dose, with the most common adverse events of having pain at the injection site, weakness, fatigue, and headache.
Conclusion: On day 28, after the second dose of 3 μg of the inactivated SARS-CoV-2 vaccine administration, a high rate of seroconversion
was observed with no serious adverse event. Natural COVID-19 history, age, and comorbidity were significant contributors to the
formation of a strong immune response. It can be concluded that a third dose may be considered in people aged 50 years and older and
those with comorbidities.
Key words: SARS-COV-2, vaccine, adverse events, immunisation, seroconversion

1. Introduction
The COVID-19 pandemic, caused by severe acute
respiratory syndrome-coronavirus 2 (SARS-CoV-2)
belonging to the genus Betacoronavirus of the family
Coronaviridae, has caused almost 153 million infections
and more than 3.2 million deaths worldwide as of May 6,
2021.1 The transmission rate is higher in SARS-CoV-2 in
comparison to other species of coronavirus [1]. Various
COVID-19 vaccines are in development around the world,
aiming to stimulate a primary immune response leading
to the development of memory B and T cells against the
SARS-CoV-2 virus and, therefore, a protection against
1

subsequent COVID-19 infections. S protein of the virus
plays an essential role in viral binding (S1 subunit), fusion
(S2), entry and transmission, and elicits highly potent
neutralizing antibodies (nAbs). The receptor-binding
domain (RBD) of S1 directly interacts with host receptors
(i.e. human-angiotensin-converting-enzyme-2) and is
the most critical target for nAbs, which interrupts this
interaction. Thus, anti-SARS-CoV-2 S-RBD IgG antibody
level in human serum or plasma correlates with protective
immune responses in individuals recovered from SARSCoV-2 infection and also reflects herd immunity at the
population level, informing clinical management of

World Health Organisation (2021). WHO Coronavirus (COVID-19) Dashboard [online]. Web site https://covid19.who.int/ [6 May 2021].
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patients with past or ongoing infection.2
Vaccines are considered the primary method for
preventing viral infections and for containing epidemics,
therefore, a vital tool in reducing mortality in a pandemic.
They are categorised according to their compositions
as adenovirus vector, mRNA, DNA, live attenuated,
inactivated, or subunit type vaccines [2]. Inactivated
vaccines incorporate viruses inactivated by using heat,
chemicals, or radiation, and they do not cause any
infection; hence, they are considered to be safe for
immunocompromised individuals. They may have some
logistical benefits like storage at room temperature. One
disadvantage is that they frequently require multiple doses
(boosters) as they do not create a cell-mediated response
[3]. They can have added adjuvants to spare doses and
increase the available quantity of the vaccines [4]. The
inactivated SARS-CoV-2 vaccine (Vero Cell) has been
shown to be safe and able to induce SARS-CoV-2 specific
nAbs in mice, rats, and nonhuman primates [5]. In phase
2 clinical trials, this vaccine was observed to produce good
immunogenicity and a low incidence of adverse events [6].
But it is still not known if formed antibodies are protective
(surrogate) in wider public use.3 This is particularly
important when we consider that none of the vaccines
in use has completed phase trials, with especially phase 4
results completely missing, as they have been introduced
for public use following Emergency Use Listing evaluation.
This study aimed to determine seroconversion rates
and levels of the neutralising and non-neutralising
antibodies, the effect of individual characteristics
including comorbidities or history of natural COVID-19
after the second dose of the inactivated SARS-CoV-2
vaccine among healthcare workers in a hospital and shortterm adverse events due to the vaccine in order to help
decision-makers by comparing doses, schedules, and the
need for additional doses.
2. Materials and methods
2.1. Study design and participants
This is a prospective cohort study carried out at Çukurova
University in March 2021 and included health workers,
who had been vaccinated with two doses of the inactivated
SARS-CoV-2 vaccine in the context of public vaccination
program by the Turkish Ministry of Health, with health
workers constituting the first line of the vaccination target
population. The permissions for the study were obtained
from the Scientific Research Platform of the Turkish
Republic Ministry of Health, Balcalı Hospital Managerial
Board, and the Scientific Ethics Committee of Faculty

of Medicine, Çukurova University (Decision no:108).
The incidence of adverse events in the vaccine cohort
was determined to be 19% after the administration of 3
μg (corresponding to 600 SU) of the inactivated SARSCoV-2 vaccine during Phase 2 clinical trials [6]. The
minimum sample size was calculated as 220 participants
by assuming type-1 error as 0.05 and type-2 error as
0.20 for the determined adverse events rate. In order to
increase the power of the study, as many participants were
included in the study as the financial budget of the project
allowed, a total of 282 participants were reached out. The
proportional distribution of the profession subgroups in
the sample (i.e. study group) reflected their distribution
in the study universe. The total number of staff working
in the hospital is 4.285, with 1052 doctors (24.6%), 1033
nurses(24.1%), and 2200 (51.3%) other groups consisting
of emergency medical technician, biologist, environmental
engineer, pharmacist, electrician, EMG technician,
security staff, nursing staff, occupational health and safety
expert, chemist, laborant, officer, audiologist, cleaning
staff, psychologist, radiology technician, secretary, driver,
and mechanist. The participants reported their working
departments under the as following names: emergency,
emergency patient admission office, COVID-19 sampling
unit, forensic case office, family medicine, operating
room, anatomy, vaccination unit, occupational health
and safety unit, neurosurgery service, IT department,
biophysics department, biostatistics department,
biomedical unit, paediatrics service, newborn service,
COVID-19 polyclinic, COVID intensive care unit,
COVID service, paediatric surgery department, paediatric
emergency department, paediatric service, internal
medicine department, oncology department, dean’s office,
archive, tissue typing laboratory, dialysis unit, pharmacy
services, pharmacy, electricity control unit, EMG unit,
endoscopy unit, infectious diseases polyclinic, infectious
diseases service, physical therapy and rehabilitation,
gastroenterology service, general surgery service,
pneumology polyclinic, pulmonology service, pulmonary
function tests unit, radiology imaging unit, eye-bank,
ophthalmology service, daily patient unit, security, patient
admission, public relations, hospital chief directorate,
hospital heating centre, haemapheresis unit, haematology
laboratory, haematology service, haematology polyclinic,
haemodialysis unit, nursing services directorate, nursing
services department, histology-embryology, nephrology,
human resources, obstetrics, in vitro fertilization centre,
quality control directorate, cardiology department, earnose-throat department, delivery room, acclimatisation

Snibe Diagnostic (2020). MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA) [online]. Web site http://multimedilab.com/wp-content/uploads/2021/01/
MAGLUMI%C2%AE-SARS-CoV-2-Neutralizing-Antibody-CLIA.pdf [29 March 2021].
2

World Health Organisation (2013). Correlates of vaccine-induced protection: methods and implications. In: Immunization, Vaccines and Biologicals
[online]. Web site https://apps.who.int/iris/bitstream/handle/10665/84288/WHO_IVB_13.01_eng.pdf [29 March 2021].
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centre, financial affairs, central laboratory, PCR unit,
central sterilization unit, directorate, nephrology,
neurology service, neurology EEG unit, neurology
intensive care, nuclear medicine, oncology, pathology,
paediatric, plastic surgery, psychiatry, radiation oncology,
radiology, radiology NMR unit, radiology secretariat,
health board, sterilization, surveillance, drivers’ office,
trusteeship department, technical coordinator, medical
biochemistry, medical genetics, deanship, faculty of
medicine multidisciplinary laboratory, urology, chief
clerkship and neonatal intensive care unit.
The participants were randomly selected from a list
of 3000 vaccinated health workers. Two substitution lists
were prepared to eliminate the possibility of missing any
participant and to preserve the pre-study randomisation.
Nobody in the main (first) list refused to participate
in the study; therefore, there has not been a need to use
the substitution lists. Blood samples were taken after the
participants had been informed about the study and had
signed an informed consent form. Blood was taken from
the participants included in the study by the experienced
and educated nurses already working at the blood
collection unit of the central laboratory of the hospital.
Since the people included in the study were both the
personnel working in our hospital and among the first
individuals that have been vaccinated, the vaccination
dates were obtained from the personnel vaccination lists.
Both the vaccination list and the appointment dates of
the individuals on the e-government application were
considered in determining the 28th day after the second
dose. The appointments were made after a large proportion
of the health workers in the hospital were vaccinated,
giving rise to the list of 3000 vaccinated personnel. The
people selected to be included in the study were identified
immediately after the second dose of the vaccines, and all
of them were contacted on their mobile phones, and their
appointments were confirmed after they had agreed to
volunteer for the study. The blood sample collection date
for each individual was given 28 days after the second dose
of vaccination. Reminder text messages were sent to people
two days before the planned time of blood collection, and
people who did not respond were recalled and reminded.
The participants answered a questionnaire form about
sociodemographic characteristics, history of a natural
COVID-19 disease, comorbidities like cardiovascular,
endocrinological, immunological, pulmonary and other
chronic diseases, vaccination, and adverse events.
2.2. Vaccine information

The generic name of the vaccine administered to health
workers by the Turkish Ministry of Health is “inactivated
SARS-CoV-2 vaccine (Vero Cell) (CoronaVacTM)”, with
aluminium hydroxide developed by Sinovac Biotech Ltd.,
Life Sciences Lab., China. The vaccine was administered
intramuscularly in the deltoid region of the upper arm with
a dosage of 3 μg/0.5 ml. The two doses were administered
28 days apart. Vaccines were transferred, stored at 2–8°C,
and administered following cold chain principles already
in use by and, therefore, familiar to health institutions
performing vaccinations.
2.3. Immunogenicity assessments
The project aimed to measure SARS-CoV-2 S-RBD
immunoglobulin G (IgG), total anti-spike and antinucleocapsid immunoglobulin M (IgM) and IgG antibody
concentrations in the same individuals repetitively in the
first, third, and sixth months. This first step of the project
aimed to reveal anti-SARS-CoV-2-S-RBD-IgG, total antispike/anti-nucleocapsid IgM and IgG concentrations at
the end of the first month after the administration of the
second dose of the inactivated vaccine. The second and
third steps of the project are planned to be performed at the
third and sixth months after the second dose, respectively.
Anti-SARS-CoV-2-S-RBD-IgG and total anti-spike/antinucleocapsid-IgG antibodies were to be measured in the
same participants. About 5 mL of blood samples were
collected into biochemistry tubes with vacuum gel. The
sera were extracted by centrifugation at 3000 × g for 10
min and kept at 2–8°C for 1–3 days. Test calibrators and
controls were worked first. After the control results were
observed to be within the expected ranges, the samples
were tested by trained experts in the accredited (by the
Joint Commission International (JCI) since 2006) Central
Laboratory of Çukurova University.
The blood samples stored at 2–8°C were brought to room
temperature on the working day and examined collectively
after all participants were sampled. The participants were
not informed about their antibody concentration at the
first month (in a single-blind format) to avoid a possible
effect on clinical complaints or outcomes as they would be
followed repetitively for 6 months.
The test method used for the qualitative detection and
differentiation of IgM (capture method) and IgG antibodies
(indirect method) to SARS-CoV-2 in human serum and
serum in separating gel tubes is a chemiluminescence
reaction based on the measurement of light signals by a
photomultiplier as relative light units (RLUs) proportional
to the concentration of antibodies present in the sample.4,5

Snibe Diagnostic (2020). MAGLUMI 2019-nCoV IgM/IgG Immunoassay [online]. Web site https://www.fda.gov/media/142233/download [29 March
2021].
Snibe Diagnostic (2020). Fact Sheet for Healthcare Providers - MAGLUMI 2019-nCoV IgM/IgG [online]. Web site https://www.fda.gov/media/142231/
download [29 March 2021].
5
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Table 1. Validity results of the test MAGLUMI 2019-nCoV IgM/IgG (Target: Spike and
Nucleocapsid)1.
Antibody

Performance Measure

Estimate of Performance(95%CI)

IgM

Sensitivity (PPA)

77.5% (69.9%–83.6%)

IgM

Specificity (NPA)

99.6% (97.5%–99.9%)

IgG

Sensitivity (PPA)

100.0% (97.4%–100.0%)

IgG

Specificity (NPA)

99.1% (96.8%–99.8%)

Combined

Sensitivity (PPA)

100% (97.4%–100.0%)

Combined

Specificity (NPA)

98.7% (96.2%–99.5%)

Combined

PPV at prevalence=5%

79.9% (57.2%–92.1%)

Combined

NPV at prevalence=5%

100.0% (99.9%–100.0%)

PPA: Positive percent agreement, NPA: Negative percent agreement, PPV: Positive predictive
value, NPV: Negative predictive value, CI: Confidence interval.
Food and Drug Administration (2021). EUA Authorized Serology Test Performance. In: Coronavirus
Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices [online]. Web site https://
www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medicaldevices/eua-authorized-serology-test-performance [29 March 2021].
1

The test is only for use according to the Food and Drug
Administration’s Emergency Use Authorization.6 The
SARS-CoV-2 S-RBD IgG test is also an indirect CLIA and
has a high correlation with VNT50 titres (R=0.712), where
VNT stands for “Virus Neutralization Test”, which is a gold
standard for quantifying the titre of nAbs for a virus [7].
The results are expressed in absorbance units (AU/mL)
and reported to the end-user as “reactive (i.e. a result ≥1.00
AU/mL)” or “non-Reactive (i.e. a result <1.00 AU/mL)”.7
The validity of the tests is summarised in Table 1.8
2.4. Statistical analyses
Data were analysed by SPSS 22 statistical analyses package
(2013, IBM, New York, U.S.A). Kolmogorov–Smirnov test
was used to test the normality for continuous variables.
Mann–Whitney U and Kruskal–Wallis tests were used
for not normally distributed variables. Fisher’s, Yates,
or Pearson chi-square tests were used for categorical
variables. A value of p < 0.05 was considered significant.
3. Results
The mean age of 282 participants included in the study
was 39.06±10.65 (min–max = 21–65). Among them,
16% reported a natural COVID-19 history before getting
vaccinated. The mean time interval between the disease and

the vaccination was calculated as 111.27±77.97 days (min–
max = 29–330). The sociodemographic characteristics and
any natural COVID-19 history of the participants are
given in Table 2.
At the first month after the administration of the second
dose of the inactivated vaccine, 277(98.2%) participants
were found to be reactive for anti-S-RBD-IgG antibodies,
262(92.9%) for total anti-spike/anti-nucleocapsid-IgG
antibodies and 43(15.2%) for total anti-spike/antinucleocapsid-IgM antibodies. When seroconversion
rates were examined according to age, sex, presence of
chronic diseases, and having natural COVID-19 prior to
vaccination, only participants with a natural history of
COVID-19 presented significantly higher seroconversion
rates for total anti-spike/anti-nucleocapsid-IgG (p = 0.027).
All individuals with non-reactive IgG concentrations
for all types of antibodies did not report a prior natural
COVID-19 (Table 3) (Figure 1).
Significantly higher antibody titrations were observed
in participants with a pre-vaccination history of natural
COVID-19, but the time interval between the disease and
the vaccination was found not to significantly alter antibody
concentrations. Total anti-spike/anti-nucleocapsid-IgG
titrations of participants aged 20–29 years were found to
be significantly higher compared to those in the 40–49

Food and Drug Administration (2021). EUA Authorized Serology Test Performance. In: Coronavirus Disease 2019 (COVID-19) Emergency Use
Authorizations for Medical Devices [online]. Web site https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-useauthorizations-medical-devices/eua-authorized-serology-test-performance [29 March 2021].
6

Snibe Diagnostic (2020). Fact Sheet for Healthcare Providers - MAGLUMI 2019-nCoV IgM/IgG [online]. Web site https://www.fda.gov/media/142231/
download [29 March 2021].
7

Food and Drug Administration (2021). EUA Authorized Serology Test Performance. In: Coronavirus Disease 2019 (COVID-19) Emergency Use
Authorizations for Medical Devices [online]. Web site https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-useauthorizations-medical-devices/eua-authorized-serology-test-performance [29 March 2021].
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Table 2. Sociodemographic characteristics and COVID-19 history of the participants (Çukurova Univ., Adana-Turkey, 2021).
Characteristics

n (%)

Total

282 (100.0)

Sex (male/female)
Male

123 (43.6)

Female

159 (56.4)

Age
20–29

69 (24.5)

30–39

83 (29.4)

40–49

75 (26.6)

50 and older

55 (19.5)

All group age (X±S.D.), min-max, median (1st–3rd quartile)

39.06 ± 10.65, 21–65, 34 (30–47)

Working position
Doctor

80 (28.4)

Nurse

62 (22.0)

Others*

140 (49.6)

Chronic disease presence

68 (24.2)

Natural COVID-19 diagnosed pre-vaccination

45 (16.0)

Pre-vaccination infection time (X±S.D.), min-max (days), median (1st-3rd quartile)

111.27±77.97, 29–330, 90 (60–150)

0–90 days

26 (57.8)

91 days and over

19 (42.2)

Severity of pre-vaccination COVID-19 disease
Mild

40 (88.9)

Moderate

5 (11.1)

* The group “Others” include emergency medical technicians, biologists, environmental engineers, pharmacists, electricians, EMG
technicians, security staff, nursing staff, occupational health and safety experts, chemists, laborants, officers, audiologists, cleaning staff,
psychologists, radiology technicians, secretaries, drivers, and mechanists.

and 50 and older age groups. Anti-S-RBD-IgG titrations
were significantly higher in the 30–39 years age group
compared to 50 and older age groups. Additionally, anti-SRBD-IgG titrations were found to be higher in individuals
with chronic diseases (Table 4) (Figure 2).
No COVID-19 cases were observed to occur in the
vaccine cohort between the two doses and until the end
of the first month after the second dose of vaccination. In
the vaccine cohort, the incidence of at least one adverse
event was found to be 29.8% between the two doses and
24.1% after the second dose with the most frequently
observed ones in both periods as pain at the injection
site, weakness, fatigue, and headache. Some participants
declared to have experienced more than one side effect.
After the first dose, multiple adverse events were observed
in 46(16.3%) participants. Concurrent adverse events were
reported as “Numbness in the vaccinated arm + Fatigue +

Weakness” and “Headache + Dizziness”. After the second
dose, multiple adverse events frequency regressed to 13.4%
(38 people), with the most frequent concurrent one being
reported as “weakness fatigue” (Table 5).
4. Discussion
In the COVID-19 pandemic, the recent introduction of
vaccines has strengthened our hand in combating the
epidemic. As of May 6, 2021, among developed vaccines,
96 are reported to be at clinical and 184 at preclinical
stage.9 But vaccines have given rise to the discussion of
new problems like how to vaccinate the whole society,
inequalities in the supply of vaccines, weaknesses in the
protection by vaccines, and resistance to get vaccinated.
It seems likely that ensuring herd immunity will be still
in action for some more time. Kuldorff et al. stated that a
focused protection approach would ensure herd immunity

World Health Organization (2021). Draft landscape and tracker of COVID-19 candidate vaccines [online]. Web site https://www.who.int/publications/m/
item/draft-landscape-of-covid-19-candidate-vaccines [21 April 2021].
9

25

26
10(9.4)
10(7.6)

Female

Male

Female

3(5.3)
4(6.3)
7(10.6)
6(11.8)

30–39

40–49

50 and above

20–29

30–39

40–49

50 and above

7(12.1)
13(7.3)

Yes

No

Yes

No

Any chronic
disease

-

20–29

Age

-

20 (7.1)

Male

Sex

Total

Non-reactive*

165(92.7)

51(87.9)

35(100.0)

10(100.0)

45(88.2)

59(89.4)

59(93.7)

54(94.7)

4(100.0)

9(100.0)

20(100.0)

12(100.0)

121(92.4)

96(90.6)

28(100.0)

17(100.0)

262 (92.9)

Reactive**

0.280

-

0.540

-

0.794

-

p

149(83.7)

51(87.9)

30(85.7)

8(80.0)

4(86.3)

54(81.8)

51(81.0)

52(91.2)

4(100.0)

8(88.9)

15(75.0)

11(91.7)

116(88.5)

85(80.2)

25(89.3)

13 (76.5)

239 (84.8)

Non-reactive*

29(16.3)

7(12.1)

5(14.3)

2(20.0)

7(13.7)

12(18.2)

12(19.0)

5(8.8)

0(0.0)

1(11.1)

5(25.0)

1(8.3)

15(11.5)

21(19.8)

3(10.7)

4(23.5)

43 (15.2)

Reactive**

0.571

1.000

0.347

0.439

0.109

0.468

p

Chi-square test (Participants with COVID-19 history were excluded in the analyses of sex, age, presence of any chronic disease).
* Number and percent of non-reactive (<1.00 AU/mL), and **Reactive (≥1.00 AU/mL) participants.

No

Yes

No

Yes

No

Yes

COVID-19 history

Characteristics

2(1.1)

3(5.2)

-

-

2(3.9)

1(1.5)

0(0)

2(3.5)

-

-

-

-

2(1.5)

3(2.8)

-

-

5 (1.8)

Non-reactive*

176(98.9)

55(94.8)

35(100.0)

10(100.0)

49(96.1)

65(98.5)

63(100.0)

55(96.5)

4(100.0)

9(100.0)

20(100.0)

12(100.0)

129(98.5)

103(97.2)

28(100.0)

17(100.0)

277 (98.2)

Reactive**

IgG

IgG

IgM

Anti-SARS-CoV-2 S-RBD

Total Anti-spike and Anti-nucleocapsid Antibodies

0.097

-

0.456

-

0.659

-

p

Table 3. Seroconversion rates at the end of the first month after the second dose of vaccination with the inactivated vaccine by some characteristics of the participants (Çukurova
Univ., Adana-Turkey, 2021).
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Figure 1. Anti-S RBD IgG (AU/mL) and total anti-spike and anti-nucleocapsid IgG (AU/mL) concentrations according to the history of
COVID-19 prior to vaccination *Yes: The participant had a history of natural COVID-19 prior to vaccination *No: The participant did
not have a history of natural COVID-19 prior to vaccination

after 3 to 6 months and then unprotected individuals
could return to normal life. Walensky stated that the herd
immunity point was not determined and that it was not
clear how stable this immunity would be. Most experts
believe this to happen in the second half of 2021 at the
earliest, and debate over what to do in the meantime seems
likely to continue. Perhaps the most important of these
discussions is the effectiveness and safety of the vaccines
in use and how long the vaccine-induced immunity will
continue and what the protection rates from the clinical
disease are. Outbreak patterns are supposed to be related
to the duration of immunity [8]. Previous studies about
other coronavirus types demonstrated that annual or
biennial patterns could be observed if the immunity
lasted 40 weeks or two years, respectively, not ignoring
the influence of cross-immunity.10 On January 13, 2021,
the inactive vaccine “CoronaVac, in suspension form
of 600 SU/0.5 mL for IM injection” was quickly granted
the Emergency Use Approval by the Turkish Ministry of
Health, aiming to reduce the spread of COVID-19 in the

community. This vaccine is currently being implemented
in 24 countries and is being evaluated also in seven phase
3 trials.11 As of August 27, 2021, a total of 91.74 million
doses were administered in Turkey, with 47.24 million of
the first dose and 36.14 million of the second.12
Our study aimed to determine the efficacy of this
inactivated vaccine administered in the context of this
program of the Turkish Ministry of Health. It is worth
reminding that the administrations were not part of any
phase trials or interventional studies. In our study, at day28 after the second dose, among participants who received
two doses of the inactivated vaccine (as 3 μg/dose), the
seroconversion rate was found to be 15.2% for total antispike/anti-nucleocapsid-IgM, 92.9% for total anti-spike/
anti-nucleocapsid-IgG and 98.2% for anti-S-RBD-IgG
antibodies. The incidence of adverse events was found as
29.8% between the two doses and 24.1% at day-28 following
the second dose, the most prominent adverse event being
pain at the injection site (16.0% between two doses of
the vaccine, and 15.6% at day-28 after the second dose),
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28

27.37 ± 40.05

No (n:237)

25.95 ± 34.48

Female (n:131)

26.01 ± 28.31

22.22 ± 35.04

28.91 ± 60.00

30–39 (n:63)

40–49 (n:66)

50 and above (n:51)

25.76 ± 31.15

No (n:178)

16.00
(0.36–168.00)

0.444*
0.98 ± 1.50

0.88 ± 1.45

0.89 ± 1.48

6.14a
(0.20–367.70)
7.78
(0.20–367.70)

1.00 ± 1.46

9.40b
(0.36–168.90)

1.00 ± 1.41

18.30
(0.48–143.50)

0.82 ± 1.28

1.12 ± 1.69

0.96 ± 1.48

0.73 ± 0.87

0.92 ± 1.40

X±S.D.

0.92 ± 1.62

0.038**

0.788*

<0.001*

p

26.26a,b
(0.54–135.60)

14.03
(0.02–198.01)

14.39
(0.37–367.70)

14.03
(0.02–367.70)

75.27
(10.16–292.40)

19.80
(0.02-367.70)

Median
(Min-Max)

0.47
(0.12–7.74)

0.52
(0.08–9.02)

0.49
(0.08–9.02)

0.49
(0.12–7.59)

0.46
(0.12–7.11)

0.48
(0.14–7.74)

0.43
(0.12–7.59)

0.52
(0.08–9.02)

0.48
(0.08–9.02)

0.47
(0.13–3.74)

0.48
(0.08–9.02)

Median
(Min-Max)

0.827*

0.938**

0.138*

0.615*

p

43.94 ± 0.20

38.07 ± 44.11

27.52 ± 29.87

41.69 ± 39.36

51.18 ± 45.96

47.09 ± 43.25

42.02 ± 40.15

43.02 ± 42.41

42.46 ± 41.09

58.31 ± 57.90

44.99 ± 44.66

X±S.D.

29.42
(0.33–161.60)

17.34
(0.10–204.20)

14.98a,b
(0.10–14.30)

23.45
(0.60–129.70)

30.07b
(1.96–204.20)

33.54a
(0.33–161.60)

29.23
(0.47–204.20)

26.84
(0.10–146.20)

27.90
(0.10–204.20)

38.99
(7.18–287.50)

29.62
(0.10–287.50)

Median
(Min-Max)

*Mann–Whitney U test, **Kruskal–Wallis test (Participants with COVID-19 history were excluded in the analyses of sex, age, presence of any chronic disease).
a,b
The cells with the same symbol are statistically significantly different as revealed by post-hoc analyses.

32.32 ± 59.96

Yes (n:58)

Any chronic disease

33.47 ± 34.07

20–29 (n:57)

Age

29.14 ± 46.13

Male (n:106)

Sex

89.74 ± 66.24

37.33 ± 50.57

Yes (n:45)

COVID-19 history

Characteristics

Total

X±S.D.

IgG (AU/mL)

IgG (AU/mL)

IgM (AU/mL)

SARS-CoV-2 S-RBD

Total Anti-spike and Anti-nucleocapsid

0.044*

0.008**

0.850*

0.033*

p

Table 4. Antibody concentrations at the end of the first month after the second dose of vaccination with the inactivated vaccine by some characteristics of the participants (Çukurova
Univ., Adana-Turkey, 2021).
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Figure 2. Anti-S RBD IgG (AU/mL) and total anti-spike and anti-nucleocapsid IgG (AU/mL) concentrations according to the age
groups (including all participants)

followed by weakness (10.6% versus 15.6%) and fatigue
(9.9% versus 10.3%) (Table.5). These correlated with the
package insert of the vaccine, based on previous clinical
studies, and classified among “the very common (>%10)
adverse reactions” like injection site pain, headache, and
fatigue.
Zhang et al. [6] performed two-phase trials (1/2) for the
same inactivated vaccine comparing 0-14 and 0-28-days
regimes and two doses (3 µg vs 6 µg). Both trials supported
our findings as better seroconversion specific to nAbs was
observed in 0-28-days cohorts. Similarly, the seroconversion
was higher in the 3µg dose group of phase-1, but in the 6
µg dose group of phase-2, although the difference was very
small (3%). Again, adverse events rates were also similar,
being lower in 3 µg dose and 0-28-day cohort in both trials,
supporting our findings (Table 5).
Xia et al. [9] performed also two-phase trials for the
same inactivated vaccine. They compared three different
doses (2.5, 5, and 10 μg) as a 0-28-56-days regime in
phase-1. If we consider 2.5 µg dose as the closest one to our
3-µg dose, the seroconversion specific to nAbs was found
as 100%. In phase-2 they compared the same dose (5 µg)
between 0-14 and 0-21-days regimes. Specific IgG binding
antibody response was better in the 0-21-day regime
(100%) compared to the 0-14-day regime (85.7%), while
seroconversion specific to nAbs was equal in both regimes.
When they compared geometric mean titres (GMT) of
nAbs and specific IgG-binding antibody responses, they
found both GMTs to be the highest in the 2.5 µg dose group
in phase-1 and in 0-21-day regime in phase-2, supporting

our findings. When Xia et al. examined adverse events
rates, the safest regime was reported in the 5-µg group of
the 0-14-day cohort. This is different from our findings, but
it is noteworthy to indicate that Xia et al reported adverse
events on day 7, which seems too early compared to our
results of 28 days.
Wu et al. [10] conducted a phase-1/2 trial, which
followed a 0-28-day regime, targeting healthy adults 60
years old and older (mean age 66.6±4.7), and found similar
results with our study regarding age profiles; a 100% of
seroconversion specific to nAbs was observed in 3 µg dose
of phase-1 and 98.0% in phase-2. Our study findings also
supported the effectiveness of this dosage and schedule.
In our study, the seroconversion rate in the 50 and older
age group was found as 89.1%, with a decreasing rate with
increasing age (95.7% in 20–29 years of age group). This
emphasizes the need for advanced phase studies in order
to clarify the immunogenicity of the inactivated vaccine
in terms of age groups and the post-vaccination period. A
comprehensive discussion comparing the results of previous
research/phase trials has been added as Supplement 2. In a
phase 3 trial about the inactivated CoronaVac performed in
Turkey by Tanrıöver et al. [11], involving 1413 participants
(981 in the vaccine group and 432 in the placebo group),
the immunogenicity analyses revealed a seropositive for
RBD-specific total antibody of 89.7% in vaccine recipients
and 4.4% in placebo recipients, with the seropositivity
decreasing with increasing age. In another study from
Turkey by Bayram et al. [12] the seropositivity for antispike antibodies was detected in 99.6% of healthcare
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Table 5. Incidences of adverse events after the first and second doses of vaccination
with the inactivated vaccine (Çukurova Univ., Adana-Turkey, 2021).
Adverse events
(n=282)

After 1st dose
n(%)

After 2nd dose
n(%)

Total

84 (29.8)

68 (24.1)

Pain at the injection site

45 (16.0)

44 (15.6)

Weakness

30 (10.6)

29 (10.3)

Fatigue

28 (9.9)

23 (8.2)

Headache

22 (7.8)

21 (7.4)

Muscle pain

12 (4.3)

5 (1.8)

Back pain

11 (3.9)

2 (0.7)

Joint pain

9 (3.2)

6 (2.1)

Dizziness

8 (2.8)

5 (1.8)

Numbness in the vaccinated arm

7 (2.5)

8 (2.8)

Vertigo

7 (2.5)

3 (1.1)

Shake

4 (1.4)

2 (0.7)

Increased blood pressure

4 (1.4)

-

Nausea

3 (1.1)

5 (1.8)

Loss of taste

3 (1.1)

2 (0.7)

Chest pain

3 (1.1)

2 (0.7)

Loss of appetite

3 (1.1)

2 (0.7)

Sore throat

3 (1.1)

1 (0.4)

Swelling at the injection site

2 (0.7)

4 (1.4)

Rash at the injection site

2 (0.7)

3 (1.1)

Diarrhoea

2 (0.7)

2 (0.7)

Fever

2 (0.7)

1 (0.4)

Palpitation

2 (0.7)

1 (0.4)

Cough

2 (0.7)

-

Numbness in the tongue

2 (0.7)

-

Decreased blood pressure

2 (0.7)

-

Others*

6 (2.4)

9 (3.5)

Each adverse event percentage was separately calculated from the total (n=282) as
there were multiple adverse events in each single participant
*Others: Stiffness at the injection site, Tinnitus, Abdominal pain, Anosmia, Balance
problem, Metallic taste

workers, antibody titres being higher in those with
COVID-19 history before vaccination. Antibody positivity
and median antibody titres were significantly lower in
healthcare workers with chronic diseases.
The results of the trials mentioned are consistent with
our findings as the dose in Turkey was almost the same (3
µg). But considering the finding that the 3-dose regimens
proved the best option has led us to hypothesise that an
additional dose could be beneficial in achieving both the
seroconversion and higher antibody concentrations. Our
hypothesis is based on our finding that all participants
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(100.0%) with a history of natural COVID-19 were reactive
for anti-S-RBD, total anti-spike and anti-nucleocapsid
IgG antibodies (p = 0.027) and antibody concentrations
were significantly higher with a median value of 38.99
(7.18–287.5) AU/mL for anti-S-RBD (p = 0.033) and 75.27
(10.16–292.40) AU/mL for the total anti-spike and antinucleocapsid IgG antibodies (p < 0.001). The details of all
referred trails are given in the Supplemental Table.
Differently from phase trials, our study did not include
solely sensitive and healthy participants; but individuals
who had previous natural COVID-19 history or
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accompanying chronic diseases were also included in the
study. Our results demonstrated that the seroconversion
rate and antibody responses were higher in individuals
who had a history of natural COVID-19. When the
immunogenicity was evaluated based on individual
characteristics; sex was not found to significantly alter
seroprevalence rate or antibody concentrations, in contrast
to age and comorbidities. The antibody response was found
to significantly decrease with increasing age. The antibody
response was found to be significantly lower in people with
chronic comorbidities. The fact that the immune response
induced by some other vaccines is affected by comorbid
conditions leading to a lower antibody response appears
to be true for the inactivated vaccines [13]. The fact that
the antibody response is lower in people over 50 years of
age and with chronic diseases indicates the need for a third
dose in these people.
To conclude, in this study, early results (step 1) of our
project indicated a high seroconversion rate for anti-S-RBD

(98.2%), total anti-spike/anti-nucleocapsid-IgG (92.9%)
antibodies, and 24-28% incidence of non-serious adverse
events. Our results are expected to help in structuring
vaccination strategies, including different age groups and
among people who had the disease. A relatively lower
antibody response in the elderly, in contrast to a relatively
higher one in people who had natural COVID-19, can
be evaluated as a need for a third dose in people lacking
antibody response after the second dose or in the elderly.
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